Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.

Kose N, Fox JM, Sapparapu G, Bombardi R, Tennekoon RN, de Silva AD, Elbashir SM, Theisen MA, Humphris-Narayanan E, Ciaramella G, Himansu S, Diamond MS, Crowe JE Jr.

Sci Immunol. 2019 May 17;4(35). pii: eaaw6647. doi: 10.1126/sciimmunol.aaw6647.

PMID:
31101672
2.

Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.

Chukwuma VU, Kose N, Sather DN, Sapparapu G, Falk R, King H, Singh V, Lampley R, Malherbe DC, Ditto NT, Sullivan JT, Barnes T, Doranz BJ, Labranche CC, Montefiori DC, Kalams SA, Haigwood NL, Crowe JE Jr.

PLoS One. 2018 Dec 19;13(12):e0209437. doi: 10.1371/journal.pone.0209437. eCollection 2018.

3.

A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.

Goo L, Debbink K, Kose N, Sapparapu G, Doyle MP, Wessel AW, Richner JM, Burgomaster KE, Larman BC, Dowd KA, Diamond MS, Crowe JE Jr, Pierson TC.

Nat Microbiol. 2019 Jan;4(1):71-77. doi: 10.1038/s41564-018-0283-7. Epub 2018 Nov 19.

4.

Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.

Flyak AI, Kuzmina N, Murin CD, Bryan C, Davidson E, Gilchuk P, Gulka CP, Ilinykh PA, Shen X, Huang K, Ramanathan P, Turner H, Fusco ML, Lampley R, Kose N, King H, Sapparapu G, Doranz BJ, Ksiazek TG, Wright DW, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr.

Nat Microbiol. 2018 Jun;3(6):670-677. doi: 10.1038/s41564-018-0157-z. Epub 2018 May 7.

5.

Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus.

Fernandez E, Kose N, Edeling MA, Adhikari J, Sapparapu G, Lazarte SM, Nelson CA, Govero J, Gross ML, Fremont DH, Crowe JE Jr, Diamond MS.

MBio. 2018 Feb 27;9(1). pii: e00008-18. doi: 10.1128/mBio.00008-18.

6.

A human antibody against Zika virus crosslinks the E protein to prevent infection.

Hasan SS, Miller A, Sapparapu G, Fernandez E, Klose T, Long F, Fokine A, Porta JC, Jiang W, Diamond MS, Crowe JE Jr, Kuhn RJ, Rossmann MG.

Nat Commun. 2017 Mar 16;8:14722. doi: 10.1038/ncomms14722.

7.

Monoclonal Antibodies Against the Staphylococcus aureus Bicomponent Leukotoxin AB Isolated Following Invasive Human Infection Reveal Diverse Binding and Modes of Action.

Thomsen IP, Sapparapu G, James DBA, Cassat JE, Nagarsheth M, Kose N, Putnam N, Boguslawski KM, Jones LS, Wood JB, Creech CB, Torres VJ, Crowe JE Jr.

J Infect Dis. 2017 Apr 1;215(7):1124-1131. doi: 10.1093/infdis/jix071.

8.

Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.

Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE Jr, de Silva AM.

J Virol. 2017 Feb 14;91(5). pii: e02041-16. doi: 10.1128/JVI.02041-16. Print 2017 Mar 1.

9.

Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice.

Sapparapu G, Fernandez E, Kose N, Bin Cao, Fox JM, Bombardi RG, Zhao H, Nelson CA, Bryan AL, Barnes T, Davidson E, Mysorekar IU, Fremont DH, Doranz BJ, Diamond MS, Crowe JE.

Nature. 2016 Dec 15;540(7633):443-447. doi: 10.1038/nature20564. Epub 2016 Nov 7.

10.

Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections.

Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, Blum DL, Hughes LJ, Satheshkumar PS, Townsend MB, Kondas AV, Reed Z, Weiner Z, Olson VA, Hammarlund E, Raue HP, Slifka MK, Slaughter JC, Graham BS, Edwards KM, Eisenberg RJ, Cohen GH, Joyce S, Crowe JE Jr.

Cell. 2016 Oct 20;167(3):684-694.e9. doi: 10.1016/j.cell.2016.09.049.

11.

Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody.

Shanker S, Czakó R, Sapparapu G, Alvarado G, Viskovska M, Sankaran B, Atmar RL, Crowe JE Jr, Estes MK, Prasad BV.

Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5830-E5837. Epub 2016 Sep 19.

12.

Recognition of influenza H3N2 variant virus by human neutralizing antibodies.

Bangaru S, Nieusma T, Kose N, Thornburg NJ, Finn JA, Kaplan BS, King HG, Singh V, Lampley RM, Sapparapu G, Cisneros A 3rd, Edwards KM, Slaughter JC, Edupuganti S, Lai L, Richt JA, Webby RJ, Ward AB, Crowe JE Jr.

JCI Insight. 2016 Jul 7;1(10). pii: e86673.

13.

Determinants of VH1-46 Cross-Reactivity to Pemphigus Vulgaris Autoantigen Desmoglein 3 and Rotavirus Antigen VP6.

Cho MJ, Ellebrecht CT, Hammers CM, Mukherjee EM, Sapparapu G, Boudreaux CE, McDonald SM, Crowe JE Jr, Payne AS.

J Immunol. 2016 Aug 15;197(4):1065-73. doi: 10.4049/jimmunol.1600567. Epub 2016 Jul 11.

14.

Frequent Use of the IgA Isotype in Human B Cells Encoding Potent Norovirus-Specific Monoclonal Antibodies That Block HBGA Binding.

Sapparapu G, Czakó R, Alvarado G, Shanker S, Prasad BV, Atmar RL, Estes MK, Crowe JE Jr.

PLoS Pathog. 2016 Jun 29;12(6):e1005719. doi: 10.1371/journal.ppat.1005719. eCollection 2016 Jun.

15.

Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization.

Willis JR, Finn JA, Briney B, Sapparapu G, Singh V, King H, LaBranche CC, Montefiori DC, Meiler J, Crowe JE Jr.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4446-51. doi: 10.1073/pnas.1518405113. Epub 2016 Apr 4.

16.

H7N9 influenza virus neutralizing antibodies that possess few somatic mutations.

Thornburg NJ, Zhang H, Bangaru S, Sapparapu G, Kose N, Lampley RM, Bombardi RG, Yu Y, Graham S, Branchizio A, Yoder SM, Rock MT, Creech CB, Edwards KM, Lee D, Li S, Wilson IA, García-Sastre A, Albrecht RA, Crowe JE Jr.

J Clin Invest. 2016 Apr 1;126(4):1482-94. doi: 10.1172/JCI85317. Epub 2016 Mar 7.

17.

Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.

Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr.

Cell. 2016 Jan 28;164(3):392-405. doi: 10.1016/j.cell.2015.12.022. Epub 2016 Jan 21.

18.

Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.

Smith SA, Nivarthi UK, de Alwis R, Kose N, Sapparapu G, Bombardi R, Kahle KM, Pfaff JM, Lieberman S, Doranz BJ, de Silva AM, Crowe JE Jr.

J Virol. 2015 Oct 28;90(2):780-9. doi: 10.1128/JVI.01805-15. Print 2016 Jan 15.

19.

Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity.

Long F, Fong RH, Austin SK, Chen Z, Klose T, Fokine A, Liu Y, Porta J, Sapparapu G, Akahata W, Doranz BJ, Crowe JE Jr, Diamond MS, Rossmann MG.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13898-903. doi: 10.1073/pnas.1515558112. Epub 2015 Oct 26.

20.

Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites.

Winarski KL, Thornburg NJ, Yu Y, Sapparapu G, Crowe JE Jr, Spiller BW.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9346-51. doi: 10.1073/pnas.1502762112. Epub 2015 Jul 13.

21.

Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.

Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, Brien JD, Austin SK, Diamond MS, Dermody TS, Crowe JE Jr.

Cell Host Microbe. 2015 Jul 8;18(1):86-95. doi: 10.1016/j.chom.2015.06.009. Erratum in: Cell Host Microbe. 2015 Sep 9;18(3):382. Khomadiak, Solomiia [corrected to Khomandiak, Solomiia].

22.

Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.

Willis JR, Sapparapu G, Murrell S, Julien JP, Singh V, King HG, Xia Y, Pickens JA, LaBranche CC, Slaughter JC, Montefiori DC, Wilson IA, Meiler J, Crowe JE Jr.

J Clin Invest. 2015 Jun;125(6):2523-31. doi: 10.1172/JCI80693. Epub 2015 May 18.

23.

Mechanism of human antibody-mediated neutralization of Marburg virus.

Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Ward AB, Saphire EO, Bukreyev A, Crowe JE Jr.

Cell. 2015 Feb 26;160(5):893-903. doi: 10.1016/j.cell.2015.01.031.

24.

Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.

Planque SA, Mitsuda Y, Chitsazzadeh V, Gorantla S, Poluektova L, Nishiyama Y, Ochsenbauer C, Morris MK, Sapparapu G, Hanson CV, Massey RJ, Paul S.

AIDS. 2014 Sep 24;28(15):2201-11. doi: 10.1097/QAD.0000000000000392.

25.

Intracellular neutralization of a virus using a cell-penetrating molecular transporter.

Sapparapu G, Sims AL, Aiyegbo MS, Shaikh FY, Harth EM, Crowe JE Jr.

Nanomedicine (Lond). 2014 Aug;9(11):1613-24. doi: 10.2217/nnm.13.139. Epub 2013 Nov 6.

PMID:
24195674
26.

Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses.

Thornburg NJ, Nannemann DP, Blum DL, Belser JA, Tumpey TM, Deshpande S, Fritz GA, Sapparapu G, Krause JC, Lee JH, Ward AB, Lee DE, Li S, Winarski KL, Spiller BW, Meiler J, Crowe JE Jr.

J Clin Invest. 2013 Oct;123(10):4405-9. doi: 10.1172/JCI69377. Epub 2013 Sep 3. Erratum in: J Clin Invest. 2013 Nov 1;123(11):4979.

27.

Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore.

Aiyegbo MS, Sapparapu G, Spiller BW, Eli IM, Williams DR, Kim R, Lee DE, Liu T, Li S, Woods VL Jr, Nannemann DP, Meiler J, Stewart PL, Crowe JE Jr.

PLoS One. 2013 May 9;8(5):e61101. doi: 10.1371/journal.pone.0061101. Print 2013.

28.

Constant domain-regulated antibody catalysis.

Sapparapu G, Planque S, Mitsuda Y, McLean G, Nishiyama Y, Paul S.

J Biol Chem. 2012 Oct 19;287(43):36096-104. doi: 10.1074/jbc.M112.401075. Epub 2012 Sep 4.

29.

Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.

Sapparapu G, Planque SA, Nishiyama Y, Foung SK, Paul S.

J Biol Chem. 2009 Sep 4;284(36):24622-33. doi: 10.1074/jbc.M109.011858. Epub 2009 Jun 19.

30.

Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds.

Taguchi H, Planque S, Sapparapu G, Boivin S, Hara M, Nishiyama Y, Paul S.

J Biol Chem. 2008 Dec 26;283(52):36724-33. doi: 10.1074/jbc.M806766200. Epub 2008 Oct 30.

Supplemental Content

Loading ...
Support Center